A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange 5379513, California 5332921 and other locations
- Dates
- study startedstudy ends around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Kura Oncology, Inc.
- ID
- NCT05735184
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 212 study participants
- Last Updated